Drug Profile


Alternative Names: JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Hoosier Cancer Research Network; Janssen; Merck & Co; Sarcoma Alliance for Research through Collaboration; TESARO; University of Utah
  • Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Breast cancer
  • Phase II Prostate cancer
  • Phase I Ewing's sarcoma; Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 08 Jun 2017 Janssen suspends participant recruitment in a phase II trial in Prostate cancer (Second-line therapy or greater, Metastatic disease, Monotherapy, Hormone-refractory) in USA, United Kingdom, Australia, Belgium, Canada, France, Spain, Sweden, South Korea, Denmark, Russia, the Netherlands and Taiwan (NCT02854436)
  • 12 May 2017 Niraparib licensed to Biologics Inc. in USA
  • 27 Apr 2017 TESARO plans a label expansion trial in multiple Cancers (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top